GlassScriptPhysician profile
Carol A Hill
NPI 1346935145
$4,104.28
in general payments reported to CMS, 2019-2025
20 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $561 · 2024: $1,396 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.28 |
| Education | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $801.83 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $766.01 | 2023-2025 | Krystexxa, Evenity, Enbrel |
| Abbvie INC. | $584.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $535.09 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $429.37 | 2023-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.68 | 2023-2024 | Ofev, Cyltezo |
| Lilly USA, LLC | $160.21 | 2023-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $144.37 | 2025 | Acthar |
| Pfizer INC. | $70.10 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.62 | 2025 | Cuvitru |
| Ani Pharmaceuticals, INC. | $57.50 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $54.43 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $54.24 | 2024-2025 | Strensiq |
| Genentech USA, INC. | $42.40 | 2024 | Actemra |
| Sandoz INC. | $41.00 | 2023 | Hyrimoz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2024 | Orencia |
| Genzyme Corporation | $29.54 | 2023 | |
| Aurinia Pharma U.S., INC. | $23.69 | 2024 | Lupkynis |
| Sobi, INC | $22.43 | 2024 | |
| Bioventus LLC | $22.36 | 2023 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.